MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Researchers at the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children's Hospital and Baylor College of Medicine recently made an important advance in neurodegenerative disease ...

Researchers have identified a key molecular interaction that accelerates Parkinson’s disease by damaging the brain’s energy ...

After three years of study, the researchers found that alpha-synuclein, a protein closely linked to Parkinson’s disease, ...

A research team led by the Institut de Neurociències at the UAB has managed to generate and validate a new animal model. This model enables the examination of the initial phases of Parkinson's disease ...

Olatec Therapeutics, Inc. ("Olatec"), a clinical stage biotechnology company leading the development of specific NLRP3 inhibitors, presented preclinical data at The Michael J. Fox Foundation (MJFF) ...

Long-term exposure to the pesticide chlorpyrifos, widely used on US farms, has been linked to a more than 2.5-fold increase in the risk of developing Parkinson's disease, according to new research.

SPARK NS and Haukeland University Hospital today announced they are collaborating on a randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the efficacy of orally administered ...

Researchers at the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children’s Hospital and Baylor College of Medicine recently made an important advance in neurodegenerative disease ...